Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature

Brent D. Van Rite, John J. Krais, Mohamad Cherry, Vassilios I. Sikavitsas, Carla Kurkjian, Roger G. Harrison

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

The L-methioninase-annexin V/selenomethionine enzyme prodrug system, designed to target the tumor vasculature and release the methylselenol anticancer drug in the tumor, was tested in mice with implanted MBA-MB-231 breast tumors. This therapy was able to cause a reduction in the size of the tumors during the treatment period. It was shown that L-methioninase-annexin V was uniformly bound at the blood vessel surface in the tumor and also that there was a substantial cutoff of blood flowing through the treated tumor, consistent with the therapy's design. This new approach for enzyme prodrug therapy of breast cancer appears promising.

Original languageEnglish
Pages (from-to)505-510
Number of pages6
JournalCancer Investigation
Volume31
Issue number8
DOIs
StatePublished - Oct 2013

Keywords

  • Biochemical markers
  • Breast cancers
  • Chemotherapy
  • Therapy

Fingerprint

Dive into the research topics of 'Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature'. Together they form a unique fingerprint.

Cite this